Suresh K. Durgam Intra Cellular Therapies, Inc. (ITCI) insider trading activity

Suresh K. Durgam is EVP, Chief Medical Officer of Intra-Cellular Therapies, Inc.. Currently has a direct ownership of 42,913 shares of ITCI, which is worth approximately $5.64 Million. The most recent transaction as insider was on Mar 10, 2025, when has been sold 3,116 shares (Common Stock) at a price of $131.24 per share, resulting in proceeds of $408,943. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 42.9K

116.7% 3M change

116.7% 12M change

Total Value Held $5.64 Million

Suresh K. Durgam Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 10 2025	SELL Payment of exercise price or tax liability	$408,943 $131.24 p/Share	3,116 Reduced 6.77%	42,913 Common Stock
Mar 10 2025	BUY Exercise of conversion of derivative security	-	7,345 Added 13.76%	46,029 Common Stock
Mar 06 2025	SELL Payment of exercise price or tax liability	$730,990 $131.19 p/Share	5,572 Reduced 12.59%	38,684 Common Stock
Mar 06 2025	BUY Exercise of conversion of derivative security	-	13,133 Added 22.88%	44,256 Common Stock
Mar 01 2025	SELL Payment of exercise price or tax liability	$475,493 $128.2 p/Share	3,709 Reduced 10.65%	31,123 Common Stock
Mar 01 2025	BUY Exercise of conversion of derivative security	-	8,742 Added 20.06%	34,832 Common Stock
Jan 31 2025	SELL Payment of exercise price or tax liability	$600,710 $127.0 p/Share	4,730 Reduced 15.35%	26,090 Common Stock
Jan 31 2025	BUY Grant, award, or other acquisition	-	11,017 Added 26.33%	30,820 Common Stock
Mar 11 2024	SELL Open market or private sale	$244,880 $65.97 p/Share	3,712 Reduced 15.79%	19,803 Common Stock
Mar 10 2024	BUY Exercise of conversion of derivative security	-	7,345 Added 23.8%	23,515 Common Stock
Mar 07 2024	SELL Open market or private sale	$429,569 $66.6 p/Share	6,450 Reduced 28.51%	16,170 Common Stock
Mar 06 2024	BUY Exercise of conversion of derivative security	-	13,132 Added 36.73%	22,620 Common Stock
Feb 26 2024	SELL Open market or private sale	$288,621 $70.19 p/Share	4,112 Reduced 30.24%	9,488 Common Stock
Feb 23 2024	BUY Exercise of conversion of derivative security	-	7,907 Added 36.76%	13,600 Common Stock
Feb 02 2024	SELL Open market or private sale	$413,744 $67.09 p/Share	6,167 Reduced 52.0%	5,693 Common Stock
Feb 01 2024	BUY Grant, award, or other acquisition	-	11,860 Added 50.0%	11,860 Common Stock
Jan 02 2024	SELL Open market or private sale	$4,421,399 $70.99 p/Share	62,282 Reduced 100.0%	0 Common Stock
Jan 02 2024	BUY Exercise of conversion of derivative security	$1,237,543 $19.87 p/Share	62,282 Added 50.0%	62,282 Common Stock
Dec 13 2023	SELL Open market or private sale	$1,382,030 $65.0 p/Share	21,262 Reduced 100.0%	0 Common Stock
Jul 17 2023	SELL Open market or private sale	$119,730 $65.0 p/Share	1,842 Reduced 7.97%	21,262 Common Stock
Mar 13 2023	SELL Open market or private sale	$328,203 $44.69 p/Share	7,344 Reduced 24.12%	23,104 Common Stock
Mar 10 2023	BUY Exercise of conversion of derivative security	-	7,344 Added 19.43%	30,448 Common Stock
Feb 24 2023	SELL Open market or private sale	$372,688 $47.14 p/Share	7,906 Reduced 25.5%	23,104 Common Stock
Feb 23 2023	BUY Exercise of conversion of derivative security	-	7,906 Added 20.32%	31,010 Common Stock
Feb 21 2023	SELL Open market or private sale	$400,992 $48.0 p/Share	8,354 Reduced 26.56%	23,104 Common Stock

SKD

Suresh K. Durgam

EVP, Chief Medical Officer

New York, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITCI shares.

Notify only if

Value

Insider Trading

Get notified when an Intra Cellular Therapies, Inc. insider buys or sells ITCI shares.

Notify only if

Operation

Value

Type

News

Receive news related to Intra-Cellular Therapies, Inc.

Track Activities on ITCI

Account